Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy

Journal of Medical Virology

Volumn 80, Issue 2, 2008, Pages 209-216

  Andersen, Ove ^a   Eugen Olsen, Jesper ^a   Kofoed, Kristian ^a   Iversen, Johan ^a   Haugaard, Steen B ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Dysmetabolism; HAART; HIV infection; suPAR

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UROKINASE RECEPTOR;

ADULT; ARTICLE; BODY FAT; BODY MASS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE SYSTEM; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID METABOLISM; LIPODYSTROPHY; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; PREDICTION; PROGNOSIS; URINALYSIS; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE;

EID: 37549009178     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21114     Document Type: Article

References (26)

1. Andersen O, Haugaard SB, Andersen UB, Friis-Moller N, Storgaard H, Volund A, Nielsen JO, Iversen J, Madsbad S. 2003. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism 52:1343-1353.
2. Blasi F, Carmeliet P. 2002. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932-943.
3. Borst SE. 2004. The role of TNF-alpha in insulin resistance. Endocrine 23:177-182.
4. Frayn KN. 1983. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55:628-634.
5. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA, Pradier C, Morfeldt L, Mateu S, Law M, El Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD. 2003. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 17:1179-1193.
6. Grimble RF. 2002. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 5:551-559.
7. Grinspoon S, Carr A. 2005. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352:48-62.
8. Haugaard SB, Andersen O, Dela F, Holst JJ, Storgaard H, Fenger M, Iversen J, Madsbad S. 2005. Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells. Eur J Endocrinol 152:103-112.
9. Hother-Nielsen O, Henriksen JE, Holst JJ, Beck-Nielsen H. 1996. Effects of insulin on glucose turnover rates in vivo: Isotope dilution versus constant specific activity technique. Metabolism 45:82-91.
10. Kolb H, Mandrup-Poulsen T. 2005. An immune origin of type 2 diabetes? Diabetologia 48:1038-1050.
11. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, Andersen O. 2003. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: Implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 285:E1072-E1080.
12. Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen BK. 2004. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 135:273-279.
13. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio MA, Knysz B, Dietrich M, Phillips AN, Lundgren JD. 2003. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 362:22-29.
14. Mustjoki S, Sidenius N, Sier CF, Blasi F, Elonen E, Alitalo R, Vaheri A. 2000. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 60:7126-7132.
15. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. 2000. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 25:312-321.
16. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H. 2004. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 35:337-342.
17. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H. 2005. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 39:23-31.
18. Petrovsky N, McNair P, Harrison LC. 1998. Diurnal rhythms of proinflammatory cytokines: Regulation by plasma cortisol and therapeutic implications. Cytokine 10:307-312.
19. Plesner T, Behrendt N, Ploug M. 1997. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 15:398-408.
20. Riisbro R, Christensen IJ, Hogdall C, Brunner N, Hogdall E. 2001. Soluble urokinase plasminogen activator receptor measurements: Influence of sample handling. Int J Biol Markers 16: 233-239.
21. Sekhar RV, Jahoor F, Pownall HJ, Ballantyne CM, Balasubramanyam A. 2004. Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy. Curr Atheroscler Rep 6:173-179.
22. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J. 2000. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96:4091-4095.
23. Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brunner N, Blasi F. 1999. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 79:717-722.
24. Vgontzas AN, Bixler EO, Lin HM, Prolo P, Trakada G, Chrousos GP. 2005. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 12:131-140.
25. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. 2002. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:455-461.
26. Yudkin JS, Juhan-Vague I, Hawe E, Humphries SE, Di Minno G, Margaglione M, Tremoli E, Kooistra T, Morange PE, Lundman P, Mohamed-Ali V, Hamsten A. 2004. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: The HIFMECH study. Metabolism 53:852-857.